Want to see CAMP full AI Analyst Report?

CAMP4 Therapeutics Corporation (CAMP) Price & Analysis

128 Followers

CAMP Stock Chart & Stats

$4.49

-$0.13(-2.84%)

At close: Jan 08 4:00 PM EST

$4.49

-$0.13(-2.84%)

Day’s Range― - ―

52-Week Range$1.32 - $7.75

Previous Close$4.45

Volume38.22K

Average Volume (3M)114.03K

Market Cap

$218.09M

Enterprise Value-$9.15M

Total Cash (Recent Filing)$99.21M

Total Debt (Recent Filing)$2.12M

Price to Earnings (P/E)―

Beta1.73

Next Earnings

Aug 13, 2026

EPS Estimate

-0.21

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.27

Shares Outstanding51,925,800

10 Day Avg. Volume180,367

30 Day Avg. Volume114,027

Financial Highlights & Ratios

PEG Ratio6.15

Price to Book (P/B)3.90

Price to Sales (P/S)53.24

P/FCF Ratio-6.24

Enterprise Value/Market Cap-0.04

Enterprise Value/Revenue-2.33

Enterprise Value/Gross Profit-3.05

Enterprise Value/Ebitda0.18

Forecast

1Y Price Target

$8.36

Price Target Upside86.13% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

EPS Forecast (FY)-0.8

Revenue Forecast (FY)$6.22M

Bulls Say, Bears Say

Bulls Say

Platform And Clinical ProgressDemonstrated preclinical efficacy for CMP-002 and a clear plan to enter a Phase 1/2 in H2 2026 meaningfully de-risks the lead program. This advances the RAP platform from discovery to clinical proof-of-concept, improving the company’s ability to attract partners or durable funding if translational results hold.

Low Financial LeverageVery low reported leverage and positive equity reduce near-term bankruptcy and interest-rate vulnerability. For a clinical-stage biotech, limited debt obligations provide flexibility to time financings, pursue development milestones, and sustain R&D investment without large fixed financing costs.

High Gross MarginsA ~70% gross margin indicates favorable unit economics for the company’s RNA-based therapies. If clinical programs scale and commercialize, strong gross margins support eventual profitability and reinvestment into R&D, making revenue growth more likely to translate into durable operating leverage.

Bears Say

High Cash BurnSustained negative operating and free cash flow of about -$26M TTM signals meaningful runway pressure for a small clinical-stage biotech. Absent near-term revenue inflection, the company will likely need dilutive equity or partnership financing within months, which can constrain strategic autonomy.

Very Small, Declining Revenue And Large LossesMinimal and declining revenue alongside an ~$86M TTM net loss underscore that the business is not yet generating sustainable commercial cash flow. Persistent operating losses erode equity and increase reliance on external financing, weakening long-term financial resilience absent clinical or revenue catalysts.

Potential Shareholder DilutionAmendments counting pre-funded warrants toward annual share increases and a new inducement plan authorizing 500k shares expand the pool available for awards and hiring. For a company needing funding, these governance actions raise realistic dilution risk for existing holders over funding cycles.

CAMP4 Therapeutics Corporation News

Camp4 Therapeutics upgraded to Overweight from Neutral at JPMorgan

JPMorgan upgraded Camp4 Therapeutics (CAMP) to Overweight from Neutral with a price target of $9, up from $5....

13d ago

CAMP

Camp4 Therapeutics initiated with a Buy at Chardan

Chardan analyst Keay Nakae initiated coverage of Camp4 Therapeutics (CAMP) with a Buy rating and $6.50 price target...

19d ago

CAMP

CAMP4 Shareholders Approve Equity Plan Changes and Inducement Plan

CAMP4 Therapeutics Corporation ( ($CAMP) ) just unveiled an announcement. On June 10, 2026, CAMP4 Therapeutics stockholders approved...

17d ago

CAMP

CAMP4 Highlights Preclinical Progress of SYNGAP1 Therapy

The latest announcement is out from CAMP4 Therapeutics Corporation ( ($CAMP) ). On May 14, 2026, CAMP4 Therapeutics...

2M ago

CAMP

Buy Rating Reaffirmed on CAMP4 as CMP-002 Advances Toward 2026 SYNGAP1 Trial and Strong Cash Runway Extends Into 2028

Analyst Yun Zhong of Wedbush maintained a Buy rating on CAMP4 Therapeutics Corporation, with a price target of...

2M ago

CAMP

Camp4 Therapeutics reports Q1 EPS (32c), consensus (21c)

Reports Q1 revenue $1.29M, consensus $1.12M. “We have made significant progress year-to-date against our goal of bringing a...

2M ago

CAMP

Camp4 Therapeutics initiated with a Buy at Rodman & Renshaw

Rodman & Renshaw analyst Seema Sheoran initiated coverage of Camp4 Therapeutics (CAMP) with a Buy rating and $7...

3M ago

CAMP

Camp4 Therapeutics price target raised to $9 from $8 at Leerink

Leerink analyst Mani Foroohar raised the firm’s price target on Camp4 Therapeutics (CAMP) to $9 from $8 and...

3M ago

CAMP

CAMP4 Therapeutics Adds Veteran CFO MacLean to Board

The latest update is out from CAMP4 Therapeutics Corporation ( ($CAMP) ). On March 18, 2026, CAMP4 Therapeutics’...

3M ago

CAMP

CAMP Earnings this Week: How Will it Perform?

CAMP4 Therapeutics Corporation (CAMP) is scheduled to report 4th quarter earnings on 03/26/2026, after the market closes. Regarding...

3M ago

CAMP

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

4M ago

CAMP

SPRB

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

4M ago

CAMP

CAMP4 Highlights 2025 Results and SYNGAP1 Program Progress

CAMP4 Therapeutics Corporation ( ($CAMP) ) has issued an announcement. On March 5, 2026, CAMP4 Therapeutics reported its...

4M ago

CAMP

Camp4 Therapeutics participates in a conf call hosted by Cantor Fitzgerald

Cantor Fitzgerald holds a conference call with CEO Mandel-Brehm on February 23 at 10 am. Published first on...

4M ago

CAMP

CAMP FAQ

What was CAMP4 Therapeutics Corporation’s price range in the past 12 months?

CAMP4 Therapeutics Corporation lowest stock price was $1.32 and its highest was $7.75 in the past 12 months.

What is CAMP4 Therapeutics Corporation’s market cap?

CAMP4 Therapeutics Corporation’s market cap is $218.09M.

When is CAMP4 Therapeutics Corporation’s upcoming earnings report date?

CAMP4 Therapeutics Corporation’s upcoming earnings report date is Aug 13, 2026 which is in 45 days.

How were CAMP4 Therapeutics Corporation’s earnings last quarter?

CAMP4 Therapeutics Corporation released its earnings results on May 07, 2026. The company reported -$0.32 earnings per share for the quarter, missing the consensus estimate of -$0.21 by -$0.11.

Is CAMP4 Therapeutics Corporation overvalued?

According to Wall Street analysts CAMP4 Therapeutics Corporation’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does CAMP4 Therapeutics Corporation pay dividends?

CAMP4 Therapeutics Corporation does not currently pay dividends.

What is CAMP4 Therapeutics Corporation’s EPS estimate?

CAMP4 Therapeutics Corporation’s EPS estimate is -0.21.

How many shares outstanding does CAMP4 Therapeutics Corporation have?

CAMP4 Therapeutics Corporation has 51,925,800 shares outstanding.

What happened to CAMP4 Therapeutics Corporation’s price movement after its last earnings report?

CAMP4 Therapeutics Corporation reported an EPS of -$0.32 in its last earnings report, missing expectations of -$0.21. Following the earnings report the stock price went up 2.765%.

Which hedge fund is a major shareholder of CAMP4 Therapeutics Corporation?

Currently, no hedge funds are holding shares in CAMP

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

CAMP4 Therapeutics Corporation Stock Smart Score

Neutral

Fundamentals

Return on Equity

-194.74%

Trailing 12-Months

Asset Growth

68.00%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

CAMP4 Therapeutics Corporation

CAMP4 Therapeutics Corporation, a biotechnology firm, was established in 2015 by Richard A. Young and Leonard Zon. Based in Cambridge, Massachusetts, its core focus is the identification and development of new therapeutic solutions for patients.

CAMP4 Therapeutics Corporation (CAMP) Earnings & Revenues

Historic Earnings Reports

CAMP Stock 12 Month Forecast

Average Price Target

$8.36

▲(86.13% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","13":"$13","3.25":"$3.25","6.5":"$6.5","9.75":"$9.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.357142857142858,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.36</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$6.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.25,6.5,9.75,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.04,4.6523076923076925,5.264615384615385,5.876923076923077,6.489230769230769,7.101538461538462,7.713846153846154,8.326153846153847,8.938461538461539,9.55076923076923,10.163076923076924,10.775384615384617,11.387692307692308,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.04,4.372087912087912,4.704175824175824,5.036263736263736,5.3683516483516485,5.700439560439561,6.032527472527473,6.364615384615385,6.696703296703297,7.028791208791209,7.360879120879121,7.692967032967033,8.025054945054945,{"y":8.357142857142858,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.04,4.229230769230769,4.418461538461538,4.607692307692307,4.796923076923077,4.986153846153846,5.1753846153846155,5.364615384615385,5.553846153846154,5.743076923076924,5.932307692307692,6.121538461538462,6.310769230769231,{"y":6.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.35,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.65,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.56,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.95,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.16,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.24,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.13,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.78,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.415,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.46,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.05,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.04,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >